Cantor Fitzgerald Forecasts Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Kura Oncology in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.94) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the company posted ($0.50) EPS.

KURA has been the topic of a number of other research reports. UBS Group assumed coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, November 19th. Jefferies Financial Group decreased their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Up 6.4 %

Kura Oncology stock opened at $7.86 on Wednesday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The firm’s fifty day moving average is $9.88 and its 200 day moving average is $16.09. The company has a market capitalization of $611.19 million, a PE ratio of -3.33 and a beta of 0.81.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of the stock. nVerses Capital LLC bought a new stake in Kura Oncology in the 3rd quarter worth about $25,000. Point72 DIFC Ltd bought a new stake in Kura Oncology in the 3rd quarter worth about $146,000. Quarry LP bought a new stake in Kura Oncology in the 2nd quarter worth about $196,000. Erste Asset Management GmbH bought a new stake in Kura Oncology in the 3rd quarter worth about $215,000. Finally, Bellevue Group AG increased its holdings in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock worth $266,000 after buying an additional 3,600 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.